Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Capital Leases Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Total Current Liabilities Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Ratios

Agios Pharmaceuticals (AGIO) Current Taxes (2021 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Current Taxes for 5 consecutive years, with $683000.0 as the latest value for Q1 2025.

For Q1 2025, Current Taxes changed N/A year-over-year to $683000.0; the TTM value through Mar 2025 reached $683000.0, changed N/A, while the annual FY2024 figure was $871000.0, N/A changed from the prior year.
Current Taxes hit $683000.0 in Q1 2025 for Agios Pharmaceuticals, down from $871000.0 in the prior quarter.
Across five years, Current Taxes topped out at $52.7 million in Q3 2024 and bottomed at $683000.0 in Q1 2025.
Average Current Taxes over 3 years is $13.8 million, with a median of $7.6 million recorded in 2021.